Up Front and Beyond the Centre Line: Australian Aborigines in Elite Australian Rules Football

Although there has been a substantial growth in the number of Aboriginal players in the Australian Football League over the past decade, issues of structural and institutional racism have not been explored. This investigation of the assignment of players by position revealed marked patterns of difference, which tend to reflect stereotypes about Aboriginal athletes. The results are similar to research conducted in the USA and the UK but suggest even stronger patterns of differentiation

Performative Pedagogy and the Creation of Desire: The Indigenous Athlete/Role Model and Implications for Learning

Abstract The athlete role model has emerged as the new pastor invested with the task of leading young people classed “at-risk” from entering into self-destructive pathways. The logic invested in the athlete role model is that young people identify with their sporting heroes and in the process try to emulate them. This holds for the major sporting codes in Australia including the Australian Football League (AFL), which supports the formation of role model programmes based on the input of Indigenous athletes to target Indigenous youth living in rural outposts. Armstrong (1996) sees the push to emulate the deeds of elite athletes in terms of a mythic function, the creation of desire to be like the hero. This article explores the theoretical implications for Indigenous learning grounded in the athlete/hero as role model. It is proposed that the athlete role model in the contemporary context of capitalism can work to obscure the realities of competition in sport and in the process promulgate false opportunity through sport at the expense of education

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

BACKGROUND Vorapaxar is a new oral protease-activated–receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. METHODS In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization. RESULTS Follow-up in the trial was terminated early after a safety review. After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar versus 1102 of 6471 patients receiving placebo (Kaplan–Meier 2-year rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P = 0.07). A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients in the vorapaxar group versus 910 in the placebo group (14.7% and 16.4%, respectively; hazard ratio, 0.89; 95% CI, 0.81 to 0.98; P = 0.02). Rates of moderate and severe bleeding were 7.2% in the vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; P<0.001). Intracranial hemorrhage rates were 1.1% and 0.2%, respectively (hazard ratio, 3.39; 95% CI, 1.78 to 6.45; P<0.001). Rates of nonhemorrhagic adverse events were similar in the two groups. CONCLUSIONS In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage